case / 31 Aug 2022

Setterwalls has assisted Enzymatica AB in connection with a rights issue of SEK 74.7 million

Responsive image

Enzymatica AB is a life science company that develops and sells health products mainly to treat diseases and symptoms in the upper respiratory tract. The products are based on a barrier technology that includes marine enzymes with unique properties. The company’s first product is the medical device product ColdZyme®, a mouth spray for common colds. The product has been launched in about 30 markets on four continents. The company is headquartered in Lund and is listed on Nasdaq First North Growth Market.

Do you want to get in touch with us?

Please fill out the form and we will contact you as soon as possible.

  • This field is for validation purposes and should be left unchanged.